




NEONATAL



ILOPROST

This document should be read in conjunction with this [DISCLAIMER](#)

 **Alert** 1 microg = 1000 nanograms

Presentation	Ampoule: 50 microg/0.5mL
Description	Synthetic analogue of prostaglandin PGI ₂
Indications	<ul style="list-style-type: none"> Persistent Pulmonary Hypertension of the Neonate (PPHN) refractory to inhaled nitric oxide and other conventional therapies.
Precaution	Can cause severe hypotension, consider use of other inotropes or vasopressors.
Dosage	<p><u>PULMONARY HYPERTENSION</u></p> <p>IV Continuous Infusion:</p> <p>Starting dose: 2 nanogram/kg/min</p> <p>If oxygenation index or PaO₂ improves, maintain this dose</p> <p>If oxygenation index remains > 20, increase by 1 nanogram/kg/min in 6 hourly intervals up to a maximum of 6 nanogram/kg/min.</p> <p>Many infants respond to 4 nanogram/kg/min.</p> <p>If no improvement in oxygenation index or PaO₂ after 24 hours consider ceasing treatment.</p>
Adverse Reactions	<p>Common: Hypotension, flushing, headache, dizziness, rash, nasal congestion, trismus.</p> <p>Serious: Serious cardiovascular disorders (including arrhythmia and sudden cardiac death), raised intra-ocular pressure, swelling of the eyelids.</p>
Monitoring	With initiation and dosage adjustments, monitor heart rate, blood pressure, and respiratory rate.
Compatible Fluids	Sodium Chloride 0.9%, Glucose 5%

Preparation	<p><u>IV Continuous Infusion:</u></p> <p><i>Dilution 1</i></p> <p>Withdraw 50 microg (0.5mL) up to 10mL with compatible fluid</p> <p>Concentration = 5 micorg/mL</p> <p><i>Dilution 2</i></p> <p>Dilute 1.2 mL/kg (6 micorg/kg) of above solution up to 50mL with compatible fluid.</p> <p><u>1mL/hr = 2 nanogram/kg/minute</u></p>
Administration	IV Continuous Infusion
References	<p>Çetin II, Ünal S, Kocabas A, Ari ME. Intravenous iloprost and oral sildenafil as rescue medicine in newborns with persistent pulmonary hypertension resistant to conventional therapy. J Clin Neonatol [serial online] 2015 [cited 2017 Jul 28];4:227-31. Available from: http://www.jcnonweb.com/text.asp?2015/4/4/227/161698</p> <p>Janjindamai W, Thatrimontrichai A, Maneenil G, Chanvitan P, Dissaneevate S. Effectiveness and safety of intravenous iloprost for severe persistent pulmonary hypertension of the newborn. Indian Pediatr. 2013 Oct;50(10):934-8. Epub 2013 Apr 5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23798625</p> <p>Lexicomp. Title Iloprost. In: UpToDate [Internet]. Alphen aan den Rijn (Netherlands): Wolters Kluwer; 2017 [cited 2017 Jul 28]. Available from: https://www.uptodate.com</p> <p>Society of Hospital Pharmacists of Australia. Iloprost. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2017 Jul 28]. Available from: http://aidh.hcn.com.au</p>
Related clinical guidelines	<u>Persistent Pulmonary Hypertension of the Newborn (PPHN)</u>

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	March 2018	Version:	1.0
Last reviewed:	July 2017	Next review date:	July 2020
Endorsed by:	Neonatal Directorate Management Group	Date:	March 2018
Standards Applicable:	NSQHS Standards: 1  Clinical Care is Guided by Current Best Practice, 4  Medication Safety;		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			

© Department of Health Western Australia 2017